Target ID & Validation
Identifying and characterizing promising therapeutic targets is the first step in the drug discovery process. Validating these targets becomes critical before investing additional time and resources for further development. Label-free binding technologies such as Bio-Layer Interferometry (BLI) and Surface Plasmon Resonance (SPR) systems are indispensable tools in target identification and validation processes where high throughput binding screens can be quickly established.
Octet® systems are used to identify binding targets and accurately characterize rates of complex formation (ka, association), complex stability (kd, dissociation) and affinities (KD)
Boost your research and commercialization goals by combining BLI and SPR at an attractive promotional price.
The Octet® family of instruments accurately measures kinetic constants by bringing the detection surface directly to the sample. This fluidics-free approach to label-free, real-time analysis streamlines laboratory workflows, expedites assay development and allows for direct measurement of crude samples.
Read Application Guide
In small molecule drug discovery, the path to lead molecules can stem from many starting points including fragment screening or de novo structural design. Determining and evaluating the affinity of small molecule binding to a therapeutic target is a significant component of the drug discovery process. The hit-to-lead and lead optimization processes are essential to accurately determine biological potency in vitro so structure-activity relationships (SAR) can be used for efficient structural design. The Octet® BLI platform and the Octet® SF3 SPR can be readily used to characterize small molecule and peptide lead candidates where both platforms provide a unique set of advantages from sensitivity, throughput and ready-to-use biosensors to match your workflow needs.
Read Technical Note
Fragment-based drug design (FBDD) has become an increasingly popular platform for the identification of lead candidates in drug discovery programs. The detection and characterization of fragment binding events is facilitated by sensitive biophysical technologies capable of detecting low-affinity interactions of low molecular weight compounds. The Octet® SF3 system has the necessary sensitivity and throughput to provide complete fragment screens on libraries of several thousand compounds in just a few weeks per target.
Read Application Note
Anti-drug antibodies (ADA) can modify the drug’s pharmacodynamics (PD) and/or pharmacokinetics (PK), making it crucial to detect them through an immun...
Modern analytical techniques designed for real-time analysis and high-throughput capabilities significantly reduce the time to the discovery
A method for evaluating the binding of an Fc gamma receptor III (FcγR) molecule to the widely characterized NIST mAb.
A comprehensive guide for designing and performing assays that accurately measure the binding kinetics of biomolecular interactions and analyte concen...
Improve the overall drug discovery process to increase the success rate of preclinical candidates
Epitope binning through cross competition assays is a powerful tool in evaluating functional diversity in antibody clones.
Using Octet® SAX Biosensors
Rapid quantitative screening of bispecific antibodies using Protein A and HIS1K biosensors
For Accurate Determination of Kinetics and Affinity Rate Constants
Antibody and other protein therapeutics are a major focus in drug discovery pipelines today
Accelerating Antibody Discovery by Monitoring Titer and Glycosylation With the Octet® Platform
Generate high-quality kinetics and affinity data in a fraction of the time compared to standard multi-cycle kinetics using the Octet® SF3.
Monitors up to 96 biosensors simultaneously, enabling label-free detection for protein quantitation and kinetic characterization at unmatched speed
Ideal for high-throughput applications that demand high sensitivity and low sample volume requirements
Unmatched flexibility and versatility in protein analysis
Get the Latest Updates, Trends and Developments on Label-free, Stress-Free Solutions for Drug Discovery, Biologics Development and Biomanufacturing.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.